A Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque Psoriasis

Phase 3 Completed 133 enrolled UCB Biopharma SRL

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary purpose of this study is to compare the efficacy of bimekizumab administered subcutaneously (sc) for 16 weeks versus placebo in the treatment of study participants with moderate to severe plaque psoriasis (PSO).

Timeline

Start: 2023-10-31
Primary completion: 2025-02-05
Completion: 2025-02-05

Outcome

Met primary endpoint

paper significantly higher primary endpoint response rates versus placebo (Week 16; PASI 90: 94.0% vs. 3.0%; IGA 0/1: 92.0% vs. 3.0%; p < 0.001 PMID 41678327 ↗

registry analysis (superiority test); ITP: Placebo vs ITP: BKZ Dosage Regimen 1; p <0.001 NCT06011733 ↗

release “Chinese study participants with moderate to severe plaque psoriasis (PSO) reported positive results. All primary and secondary endpoints were met” ucb.com ↗

Publications

Results Cai L, Man XY, Wang J, Wei A, Chen Y, Deherder D, Gao J, Hoepken B, Sun W, Lei T, Zhang J; BE SHINING Study Group. Bimekizumab efficacy and safety in Chinese patients with psoriasis in the BE SHINING Phase 3 study. J Eur Acad Dermatol Venereol. 2026 Jun;40(6):1019-1029. doi: 10.1111/jdv.70350. Epub 2026 Feb 12.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bimekizumab	Monoclonal antibody	320 mg	Subcutaneous